Dr. Kojouri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
307 S 13th St
Mount Vernon, WA 98274Phone+1 360-814-2146Fax+1 360-814-2445
Education & Training
University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2004 - 2006- University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 2001 - 2004
Tehran University of Medical Sciences School of MedicineClass of 1991
Certifications & Licensure
WA State Medical License 2009 - 2025
OK State Medical License 2003 - 2010
Clinical Trials
- Nab-Paclitaxel and Bevacizumab Followed By Bevacizumab and Erlotinib in Metastatic Breast Cancer Start of enrollment: 2008 Apr 23
- Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients Start of enrollment: 2013 Jul 19
- Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- 10 citationsAn 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML.Mohamed L Sorror, Ted A Gooley, Barry E Storer, Aaron T Gerds, Mikkael A Sekeres
Blood. 2023-01-19 - Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia.Mohamed L Sorror, Barry E Storer, Amir T Fathi, Andrew Brunner, Aaron T Gerds
Blood. 2021-08-05 - Multi-Site 11-Year Experience of Less-Intensive versus Intensive Therapies in Acute Myeloid Leukemia.Mohamed L. Sorror, Barry E. Storer, Amir T. Fathi, Andrew M. Brunner, Aaron T. Gerds
Blood. 2021-04-28
Lectures
- Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observati...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
